Neuroactive steroids, mood stabilizers, and neuroplasticity: Alterations following lithium and changes in Bcl-2 knockout mice

International Journal of Neuropsychopharmacology

Volumn 11, Issue 4, 2008, Pages 547-552

  Marx, Christine E ^a,b   Yuan, Peixiong ^c   Kilts, Jason D ^a,b   Madison, Roger D ^a,b   Shampine, Lawrence J ^a,b   Manji, Husseini K ^c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Allopregnanolone; Frontal cortex; Neurosteroid; Pregnenolone; Valproate

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; LITHIUM CARBONATE; PREGNENOLONE; PROTEIN BCL 2; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG POTENTIATION; FRONTAL CORTEX; GAS CHROMATOGRAPHY; KNOCKOUT MOUSE; LOW DRUG DOSE; MALE; MASS SPECTROMETRY; NERVE CELL PLASTICITY; NONHUMAN; PRIORITY JOURNAL; RAT; WILD TYPE;

AFFECT; ANIMALS; ANTIMANIC AGENTS; CHROMATOGRAPHY, GAS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DNA; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; GENES, BCL-2; LITHIUM CHLORIDE; MALE; MICE; MICE, KNOCKOUT; NEURONAL PLASTICITY; PREFRONTAL CORTEX; PREGNANOLONE; PREGNENOLONE; RATS; RATS, INBRED WKY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VALPROIC ACID;

EID: 44349155318     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145708008444     Document Type: Article

References (34)

1. Baldessarini RJ, Tondo L, Davis P, Pompili M, Goodwin FK, Hennen J (2006). Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review. Bipolar Disorders 8, 625-639.
2. Barbaccia ML, Affricano D, Purdy RH, Maciocco E, Spiga F, Biggio G (2001). Clozapine, but not haloperidol, increases brain concentrations of neuroactive steroids in the rat. Neuropsychopharmacology 25, 489-497.
3. A receptor. Nature Reviews Neuroscience 6, 565-575.
4. Bradford DW, Shampine LJ, Payne VM, Naylor JC, Massing MW, Xie YN, Lieberman JA, Morrow AL, Marx CE (2006). Pregnenolone alterations in parietal cortex are associated with death by suicide in patients with schizophrenia. American College of Neuropsychopharmacology Annual Meeting, Hollywood, FL.
5. Charalampopoulos I, Tsatsanis C, Dermitzaki E, Alexaki VI, Castanas E, Margioris AN, Gravanis A (2004). Dehydroepiandrosterone and allopregnanolone protect sympathoadrenal medulla cells against apoptosis via antiapoptotic Bcl-2 proteins. Proceedings of the National Academy of Sciences USA 101, 8209-8214.
6. Chen G, Rajkowska G, Du F, Seraji-Bozorgzad N, Manji HK (2000). Enhancement of hippocampal neurogenesis by lithium. Journal of Neurochemistry 75, 1729-1734.
7. Chen G, Zeng WZ, Yuan PX, Huang LD, Jiang YM, Zhao ZH, Manji HK (1999). The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. Journal of Neurochemistry 72, 879-882.
8. Chuang DM (2005). The antiapoptotic actions of mood stabilizers: molecular mechanisms and therapeutic potentials. Annals of the New York Academy of Sciences 1053, 195-204.
9. Djebaili M, Guo Q, Pettus EH, Hoffman SW, Stein DG (2005). The neurosteroids progesterone and allopregnanolone reduce cell death, gliosis, and functional deficits after traumatic brain injury in rats. Journal of Neurotrauma 22, 106-118.
10. Einat H, Yuan P, Manji HK (2005). Increased anxiety-like behaviors and mitochondrial dysfunction in mice with targeted mutation of the Bcl-2 gene: Further support for the involvement of mitochondrial function in anxiety disorders. Behavioural Brain Research 165, 172-180.
11. Gray NA, Zhou R, Du J, Moore GJ, Manji HK (2003). The use of mood stabilizers as plasticity enhancers in the treatment of neuropsychiatric disorders. Journal of Clinical Psychiatry 64 Suppl 5, 3-17.
12. Griffin LD, Gong W, Verot L, Mellon SH (2004). Niemann-Pick type C disease involves disrupted neurosteroidogenesis and responds to allopregnanolone. Nature Medicine 10, 704-711.
13. Hardoy MC, Serra M, Carta MG, Contu P, Pisu MG, Biggio G (2006). Increased neuroactive steroid concentrations in women with bipolar disorder or major depressive disorder. Journal of Clinical Psychopharmacology 26, 379-384.
14. Hennion JP, el-Masri MA, Huff MO, el-Mailakh RS (2002). Evaluation of neuroprotection by lithium and valproic acid against ouabain-induced cell damage. Bipolar Disorders 4, 201-206.
15. Jin N, Kovacs AD, Sui Z, Dewhurst S, Maggirwar SB (2005). Opposite effects of lithium and valproic acid on trophic factor deprivation-induced glycogen synthase kinase-3 activation, c-Jun expression and neuronal cell death. Neuropharmacology 48, 576-583.
16. Kokate TG, Cohen AL, Karp E, Rogawski MA (1996). Neuroactive steroids protect against pilocarpine- and kainic acid-induced limbic seizures and status epilepticus in mice. Neuropharmacology 35, 1049-1056.
17. Marx CE, Shampine LJ, Duncan GE, VanDoren MJ, Grobin AC, Massing MW, Madison RD, Bradford DW, Butterfield MI, Lieberman JA, Morrow AL (2006a). Clozapine markedly elevates pregnenolone in rat hippocampus, cerebral cortex, and serum: candidate mechanism for superior efficacy? Pharmacology, Biochemistry and Behavior 84, 598-608.
18. Marx CE, Stevens RD, Shampine LJ, Uzunova V, Trost WT, Butterfield MI, Massing MW, Hamer RM, Morrow AL, Lieberman JA (2006b). Neuroactive steroids are altered in schizophrenia and bipolar disorder: relevance to pathophysiology and therapeutics. Neuropsychopharmacology 31, 1249-1263.
19. Marx CE, Trost WT, Shampine LJ, Stevens RD, Hulette CM, Steffens DC, Ervin JF, Butterfield MI, Blazer DG, Massing MW, Lieberman JA (2006c). The neurosteroid allopregnanolone is reduced in prefrontal cortex in Alzheimer's disease. Biological Psychiatry 60, 1287-1294.
20. Marx CE, VanDoren MJ, Duncan GE, Lieberman JA, Morrow AL (2003). Olanzapine and clozapine increase the GABAergic neuroactive steroid allopregnanolone in rodents. Neuropsychopharmacology 28, 1-13.
21. Mayo W, Lemaire V, Malaterre J, Rodriguez JJ, Cayre M, Stewart MG, Kharouby M, Rougon G, Le Moal M, Piazza PV, Abrous DN (2005). Pregnenolone sulfate enhances neurogenesis and PSA-NCAM in young and aged hippocampus. Neurobiology of Aging 26, 103-114.
22. Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, Bourgeois M, Chouinard G, Islam MZ, Kane J, et al. (2003). Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Archives of General Psychiatry 60, 82-91.
23. +. European Journal of Biochemistry 266, 886-891.
24. Mora A, Sabio G, Alonso JC, Soler G, Centeno F (2002). Different dependence of lithium and valproate on PI3K/PKB pathway. Bipolar Disorders 4, 195-200.
25. Morrow AL, Suzdak PD, Paul SM (1987). Steroid hormone metabolites potentiate GABA receptor-mediated chloride ion flux with nanomolar potency. European Journal of Pharmacology 142, 483-485.
26. Oakley PW, Whyte IM, Carter GL (2001). Lithium toxicity: an iatrogenic problem in susceptible individuals. Australia and New Zealand Journal of Psychiatry 35, 833-840.
27. Schule C, Baghai TC, di Michele F, Eser D, Pasini A, Schwarz M, Rupprecht R, Romeo E (2007). Effects of combination treatment with mood stabilizers and mirtazapine on plasma concentrations of neuroactive steroids in depressed patients. Psychoneuroendocrinology 32, 669-680.
28. Suppes T, Webb A, Paul B, Carmody T, Kraemer H, Rush AJ (1999). Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. American Journal of Psychiatry 156, 1164-1169.
29. Tohen M, Jacobs TG, Grundy SL, McElroy SL, Banov MC, Janicak PG, Sanger T, Risser R, Zhang F, Toma V, et al. (2000). Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group. Archives of General Psychiatry 57, 841-849.
30. Tollefson GD, Sanger TM, Beasley CM, Tran PV (1998). A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia. Biological Psychiatry 43, 803-810.
31. Uzunova V, Sampson L, Uzunov DP (2006). Relevance of endogenous 3a-reduced neurosteroids to depression and antidepressant action. Psychopharmacology 186, 351-361.
32. Wang JM, Johnston PB, Ball BG, Brinton RD (2005). The neurosteroid allopregnanolone promotes proliferation of rodent and human neural progenitor cells and regulates cell-cycle gene and protein expression. Journal of Neuroscience 25, 4706-4718.
33. Wieland S, Lan NC, Mirasedeghi S, Gee KW (1991). Anxiolytic activity of the progesterone metabolite 5α-pregnan-3α-ol-20-one. Brain Research 565, 263-268.
34. Xilouri M, Papazafiri P (2006). Anti-apoptotic effects of allopregnanolone on P19 neurons. European Journal of Neuroscience 23, 43-54.